TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 فبراير 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

06 يناير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 ديسمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

25 نوفمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

12 نوفمبر 2024 16:21:02 بحسب Nasdaq GlobeNewswire

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

12 نوفمبر 2024 08:00:02 بحسب Nasdaq GlobeNewswire

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

10 أكتوبر 2024 07:01:00 بحسب Nasdaq GlobeNewswire

Tempest Extends Limited Duration Stockholder Rights Plan

10 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20 سبتمبر 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

18 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

21 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

15 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

08 أغسطس 2024 16:56:29 بحسب Nasdaq GlobeNewswire

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

20 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

18 يونيو 2024 18:22:51 بحسب Nasdaq GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 يونيو 2024 04:30:00 بحسب Nasdaq GlobeNewswire

Tempest to Participate in Upcoming Investor Conferences

21 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

09 مايو 2024 16:29:27 بحسب Nasdaq GlobeNewswire